Search Results - Eric Lawitz

Refine Results
  1. 1
    The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study

    The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study by Matthew J. Hepburn, Jeffrey A. Vos, Eric P. Fillman, Eric Lawitz

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

    GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) by Naim Alkhouri, Eric Lawitz, Mazen Noureddin, Ralph A. DeFronzo, Gerald I. Shulman

    Published 2019
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938

    Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938 by Jérémie Guedj, Phillip S. Pang, Jill Denning, M. Rodríguez‐Torres, Eric Lawitz, William T. Symonds, Alan S. Perelson

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

    Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885 by Kelly A. Wong, Angela Worth, Ross Martin, Evguenia Svarovskaia, Diana M. Brainard, Eric Lawitz, Michael D. Miller, Hongmei Mo

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens

    Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens by Zobair M. Younossi, Maria Stepanova, Fatema Nader, Ira M. Jacobson, Ed Gane, David R. Nelson, Eric Lawitz, Sharon Hunt

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

    Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis by Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory‐Sobol, William T. Symonds, John G. McHutchison, Fernando E. Membreno

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

    Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein by Eric Lawitz, Hadas Dvory‐Sobol, Brian Doehle, Angela Worth, John McNally, Diana M. Brainard, John O. Link, Michael D. Miller, Hongmei Mo

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A phase 1, randomized, dose‐ranging study of <scp>GS</scp>‐5816, a once‐daily <scp>NS</scp>5A inhibitor, in patients with genotype 1–4 hepatitis C virus

    A phase 1, randomized, dose‐ranging study of <scp>GS</scp>‐5816, a once‐daily <scp>NS</scp>5A inhibitor, in patients with genotype 1–4 hepatitis C virus by Eric Lawitz, Bradley Freilich, John O. Link, Polina German, H. Mo, Lingling Han, Diana M. Brainard, J. McNally, Thomas Marbury, M. Rodríguez‐Torres

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection

    Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection by Elliot B. Tapper, E. Cohen, Keyur Patel, Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz, David R. Nelson, Imad Nasser, Tracy Challies, Nezam H. Afdhal

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat

    Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat by Eric Lawitz, Bal Raj Bhandari, Peter Ruane, Anita Kohli, Eliza Harting, Dora Ding, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Rohit Loomba

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

    Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis by Ira M. Jacobson, Eric Lawitz, Paul Y. Kwo, Christophe Hézode, Cheng‐Yuan Peng, Anita Y. M. Howe, Peggy Hwang, Janice Wahl, Michael Robertson, Eliav Barr, Barbara Haber

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

    Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C by Fred Poordad, Eric Lawitz, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Sara Siggelkow, M. Heckaman, Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Edward Tam, Barry Bernstein

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

    BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial by Eric Lawitz, Diane E. Shevell, Giridhar Tirucherai, Shuyan Du, Warner Chen, Uma Kavita, Angie Coste, Fred Poordad, M.A. Karsdal, Mette Juul Nielsen, Zachary Goodman, Edgar D. Charles

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

    Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial by Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J. Sanyal, Jörn M. Schattenberg, Philip N. Newsome

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

    Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial by Rohit Loomba, Pierre Bédossa, Katharine Grimmer, George Kemble, Eduardo B. Martins, William McCulloch, Marie O’Farrell, Wen-Wei Tsai, Jose Cobiella, Eric Lawitz, Madhavi Rudraraju, Stephen A. Harrison

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial

    869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results Fr... by Eric Lawitz, Xavier Forns, Stefan Zeuzem, Edward Gane, Jean‐Pierre Bronowicki, Pietro Andreoné, Andrzej Horban, Ashley Brown, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk‐Mahadevan, Ronald Kalmeijer, Maria Beumont‐Mauviel

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

    Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis by Eric Lawitz, Mihály Makara, Ulus Salih Akarca, Paul J. Thuluvath, Liliana Preoțescu, Peter Varunok, Rosa Ma Morillas, Coleen Hall, Niloufar Mobashery, Rebecca Redman, Edward Tam, Regis A. Vilchez, Christophe Hézode

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

    Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection by Eric Lawitz, William O’Riordan, Armen Asatryan, B. Freilich, Terry Box, J. Scott Overcash, Sandra Lovell, Teresa I. Ng, Wei Liu, Andrew Campbell, Chih-Wei Lin, Betty Yao, Jens Kort

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH

    Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH by Naim Alkhouri, Carl LaCerte, Jeffrey E. Edwards, Fred Poordad, Eric Lawitz, Lois K. Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Chen Jianfen, Jason Campagna

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

    Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease by Paul J. Pockros, K. Rajender Reddy, Parvez Mantry, E. Cohen, Michael Bennett, Mark Sulkowski, David Bernstein, Daniel E. Cohen, Nancy S. Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: